



Keeping pace with industrial development and market demand, Medicilon's experienced Pharmacology and Pharmacodynamics Department has established a complete animal model evaluation system based on verification, precision, and efficacy testing. We have a broad spectrum of tumor models established in both mouse and rat.

With more than 20 years of experience, Medicilon has **510+** tumor models, including CDX models, PDX models, Syngeneic models, Humanized models, Orthotopic models and more.

We have a professional team with profound scientific knowledge and many years of experimental experiences and have the most up to date experimental facilities to comprehensively study the efficacy of various categories of test articles, from the molecular level, cellular level, and platform. Preclinical systematic efficacy evaluation can be conducted on multiple administration routes (including oral gavage, injections, topical application, nasal drops, sprays, etc.). Test articles include small molecule chemicals, monoclonal antibodies, ADC drugs, cell therapy modalities, and traditional Chinese medicine, etc. We can provide comprehensive and authentic data and reports for IND filing. It has been highly recognized by customers in the drug discovery industry, domestically and internationally.

At the same time, we are continuously developing new platforms to empower innovative therapies. We have completed many model establishment and efficacy studies of advanced therapies such as CAR-T, TCR-T, CAR-NK, nucleic acid, oncolytic virus, and AAV.

## CDX Models

Cancer Type	Cell Line
Brain cancer	CHP-212, LN-229, U-87 MG, U-251 MG
Breast cancer	BT474, HCC70, HCC1569, HCC1806, HCC1954, JIMT-1, MCF7, MDA-MB-231, MDA-MB-436, MDA-MB-468, MX-1, SUM 149PT, ZR-75-1
Cervix	Hela, SiHa
Colon cancer	COLO 205, DLD-1, HCT-8, HCT-15, HCT-116, HT-29, LIM-1215, LoVo, Ls174T, NCI-H508, RKO, SW48, SW480, SW620, SW837
Endometrium	AN3 CA, HEC-1-A, HEC-1-B, RL95-2
Esophageal	KYSE-520
Fibrosarcoma/Soft tissue	HT-1080
Gastric cancer	Hs 746T, MKN-45, NCI-N87, NUGC-4, SNU-16
Head and neck cancer	CAL-27, Detroit562, FaDu, TT
Leukemia	CCRF-CEM, HEL, HL-60, Jurkat E6.1, JVM-3, K-562, MOLM-13, MOLM-16, MOLT-3, MOLT-4, MV-4-11, OCI-AML-3, TF-1a, THP-1, U-937
Liver cancer	HCCLM3, Hep G2, HuH-7
Lung cancer	A427, A549, Calu-1, Calu-3, Calu-6, DMS114, EBC-1, HCC827, MOTO-211H, NCI-H69, NCI-H292, NCI-H358, NCI-H460, NCI-H520, NCI-H522, NCI-H526, NCI-H727, NCI-H820, NCI-H1299, NCI-H1373, NCI-H1568, NCI-H1581, NCI-H1650, NCI-H1703, NCI-H1975, NCI-H2122, NCI-H2228, NCI-H3122, NCI-H3255, PC9
Lymphoma	Daudi, DB, DOHH2, HH, JeKo-1, Karpas299, MAVER-1, Mino, OCI-LY10, OCI-LY19, Raji, RL, SR, SU-DHL-1, SU-DHL-2, SU-DHL-4, SU-DHL-6, TMD-8, WSU DLCL2
Melanoma	A375, C32
Myeloma	MM.1R, MM.1S, NCI-H929, OPM-2, RPMI-8226
Osteosarcoma	SJSA-1
Ovary	A2780, OVCAR-3, OVCAR-8, PA-1, SK-OV-3
Pancreatic cancer	AsPC-1, Bx PC-3, Capan-1, Capan-2, CFPAC-1, HPAF-II, Mia PaCa-2, PANC-1, SU.86.86, SW1990
Prostate	22RV1, DU145, LnCap, LNCaP-F877L mut, PC-3, Vcap
Renal cancer	786-O, A498, ACHN, OS-RC-2
Skin cancer	A-431
Urinary bladder cancer	5637, HT1376, RT4, UM-UC-3

## PDX Models

Cancer Type	Cell Line
Breast cancer	201B, 203B
Cervix	371Ce
Colon cancer	002C, 008C, 011C, 013C, 015C, 016C, 020C, 021C, 057C, 058C, 059C, 060C, 061C, 062C, 064C, 065C, 069C, 070C, 072C, 075C, 076C, 084C, 087C, 088C, 095C, 102C, 104C, 110C, 116cC, 117C, 128C, 143C
Endometrium	361En
Esophagus cancer	341Es
Gastric cancer	091Ga, 092Ga, 122Ga, 126Ga, 142Ga, 145Ga, 254Ga, 256Ga, 258Ga, 259Ga, 381Ga
Head and neck cancer	281T, 285HN, 284HN, 286HN
Leukemia	291Le, 292Le, 293Le, 294Le, 295Le
Liver cancer	212Li, 213Li, 214Li, 216Li
Lung cancer	028Lu, 047Lu, 050Lu, 053Lu, 054Lu, 263Lu, 264Lu, 265Lu, 267Lu
Lymphoma	244Ly, 245Ly
Myeloma	321Bm
Ovary	271O, 272O, 273O, 274O
Pancreatic cancer	221Pa, 222Pa, 223Pa, 224Pa, 225Pa, 226Pa, 228Pa
Prostate	351Pr, 353Pr, 354Pr, 355Pr
Renal cancer	301R, 303R, 304R
Sarcoma	332Sa, 333Sa, 334Sa
Urinary bladder cancer	232U, 234U, 235U, 236U

## Syngeneic Models

Cancer Type	Cell Line
Brain cancer	Neuro-2a
Breast cancer	4T1, EMT6, EO771, JC
Colon cancer	Colon26, CT26.WT, MC-38
Leukemia	C1498, L1210, WEHI-3
Liver cancer	H22
Lung cancer	KLN205, LLC1, M109
Lymphoma	A20, E.G7-OVA, EL4, L5178-R
Mastocytoma	P815
Melanoma	B16, B16-F0, B16-F10, Clone-M3, YUMM1.7
Myeloma	J558
Pancreas cancer	KPC, Panc 02
Prostate	RM-1
Renal cancer	RENCA
Sarcoma	S180, WEHI-164
Urinary bladder cancer	MB49

## Humanized Models (PBMC, HSC CD34+)

Cancer Type	Cell Lines in PBMC or HSC CD34+ Humanized Mice
Brain cancer	U-87 MG
Breast cancer	HCC70, HCC1954, JIMT-1, MDA-MB-231, MDA-MB-468
Colon cancer	HT-15, HT29, LoVo, Ls174T
Gastric cancer	NCI-N87, NUGC-4
Leukemia	MOLM-13, THP-1
Liver cancer	Hep G2, HuH-7
Lung cancer	A549, HCC827, NCI-H292, NCI-H838, NCI-H1975
Lymphoma	Raji, TMD8
Melanoma	A375
Myeloma	MM.1S, NCI-H929, RPMI-8226
Ovarian cancer	OVCAR-3
Pancreatic cancer	Capan-2
Renal cancer	786-O, A498
Skin cancer	A431
Urinary bladder cancer	UM-UC-3

## Orthotopic Models

Cancer Type	Orthotopic Model (Human)	Orthotopic Model (Mouse)
Brain cancer	LN299-luc, U87-MG-luc, U251-luc	G261-luc
Breast cancer	BT-474-luc, MCF-7-luc,MDA-MB-231-luc	4T1-luc
Colon cancer	HCT-116-luc, HT29-luc	MC38-luc
Gastric cancer	NCI-N87-luc	/
Leukemia	K562-luc, MOLM-13-luc, MV-4-11-luc, Nalm-6-luc, THP-1-luc	/
Liver cancer	HuH-7-luc, Hep G2-luc	H22-luc
Lung cancer	A549-luc, NCI-H460, NCI-H1650-luc, NCI-H1975-luc	LLC1-luc
Lymphoma	Raji-luc, JeKo-1-luc	/
Melanoma	A375-luc	B16-F10-luc
Myeloma	NCI-H929-luc, MM.1S-luc, OPM-2-luc	/
Ovary	OVCAR-3-luc, SK-OV-3-luc	/
Pancreatic cancer	Mia-Paca 2-luc, PANC-1-luc	Panc 02-luc
Prostate	PC-3-luc	/
Renal cancer	A498-luc	/
Sarcoma	HT1080-luc, SJSA-1-luc	/
Urinary bladder cancer	UM-UC-3-luc	MB49-luc



### MEDICILON

**Email:** [marketing@medicilon.com](mailto:marketing@medicilon.com) **Website:** [www.medicilon.com](http://www.medicilon.com)

**Address:** > 20 Maguire Road, Suite 103, Lexington, MA 02421, USA  
> 585 Chuanda Road, Pudong, Shanghai, 201299, China